Skip to main content

Advertisement

SpringerLink
Log in

Non-hormonal Chemoprevention

  • Risk and Prevention (ME Wood, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of review

Potential strategies for prevention of breast cancer include lifestyle modification, preventive therapies (i.e., chemoprevention), and surgical prevention. Several therapies (such as selective estrogen response modifiers and aromatase inhibitors) have been shown to prevent breast cancer. However, tolerability and toxicity limit use and these therapies only prevent estrogen receptor–positive (ER) disease. There is emerging data regarding prevention properties of several non-hormonal agents. These agents generally have lower toxicities and seem to be effective for reduction of both ER+ and ER− disease and are often approved for use in other diseases. The purpose of this review is to discuss the data supporting the potential role of these non-hormonal agents for breast cancer prevention.

Recent findings

Several studies have demonstrated the potential of aspirin, vitamin D, metformin, and bisphosphonates to prevent breast cancer.

Summary

The outlined studies support biological mechanisms and show epidemiologic associations but randomized controlled trials are necessary before any of these agents can be recommended for breast cancer prevention. Given the wide spread use of these agents, significant consideration to trial design is needed (i.e., focus on high-risk populations and use of biomarker endpoints). Another important consideration may be the investigation of combinations of agents as suggested by others.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet; 2015 386(10001): 1353–1361.

  2. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518–27.

    Article  CAS  PubMed  Google Scholar 

  3. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010;9(1):188–97.

    Article  CAS  PubMed  Google Scholar 

  4. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, et al. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016;158(1):67–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730–7.

    Article  CAS  PubMed  Google Scholar 

  6. Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, et al. Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc. 2016;91(1):71–80.

    Article  CAS  PubMed  Google Scholar 

  7. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149–55.

    Article  CAS  PubMed  Google Scholar 

  8. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T. Prostaglandins and breast cancer. Lancet. 1977;2(8039):624–6.

    Article  CAS  PubMed  Google Scholar 

  9. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160(15):2363–8.

    Article  CAS  PubMed  Google Scholar 

  10. Blot WJ, Brinton LA, Fraumeni JF Jr, Stone BJ. Cancer mortality in U.S. counties with petroleum industries. Science. 1977;198(4312):51–3.

    Article  CAS  PubMed  Google Scholar 

  11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33(6):1304–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23(34):8606–12.

    Article  PubMed  Google Scholar 

  13. Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Ahern TP. Statin use and breast cancer risk in the nurses' health study. Cancer Epidemiol Biomark Prev. 2016;25(1):201–6.

    Article  CAS  Google Scholar 

  14. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomark Prev. 2011;20(1):101–11.

    Article  CAS  Google Scholar 

  15. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–15.

    Article  CAS  PubMed  Google Scholar 

  16. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100(11):2308–16.

    Article  CAS  PubMed  Google Scholar 

  17. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–8.

    Article  PubMed  Google Scholar 

  18. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control. 2011;22(7):965–75.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Brisson J, Berube S, Diorio C, Masse B, Lemieux J, Duchesne T, et al. A randomized double-blind placebo-controlled trial of the effect of vitamin D3 supplementation on breast density in premenopausal women. Cancer Epidemiol Biomark Prev. 2017;26(8):1233–41.

    Article  CAS  Google Scholar 

  20. Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2011;15(3):501–13.

    Article  CAS  PubMed  Google Scholar 

  21. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120(4):833–43.

    Article  CAS  PubMed  Google Scholar 

  22. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66(17):8707–14.

    Article  CAS  PubMed  Google Scholar 

  23. Cauley JA, Chlebowski RT, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the women's health initiative. J Women's Health (Larchmt). 2013;22(11):915–29.

    Article  Google Scholar 

  24. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Women's Health (Larchmt). 2003;12(8):749–56.

    Article  Google Scholar 

  25. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.

    Article  CAS  PubMed  Google Scholar 

  26. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28(22):3582–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100(22):1581–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012;30(23):2844–52.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Clezardin P, Benzaid I, Croucher PI. Bisphosphonates in preclinical bone oncology. Bone. 2011;49(1):66–70.

    Article  CAS  PubMed  Google Scholar 

  30. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006.

    Article  CAS  PubMed  Google Scholar 

  31. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the women's health study: a randomized controlled trial. JAMA. 2005;294(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  32. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77–85.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14(12):2803–15.

    Article  CAS  PubMed  Google Scholar 

  34. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.

    Article  CAS  Google Scholar 

  35. Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, et al. Safety, feasibility, and biomarker effects of high-dose vitamin D supplementation among women at high risk for breast cancer. Int J Food Sci Nutr Diet. 2015;2015(Suppl 1):1–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12(5):496–503.

    Article  CAS  PubMed  Google Scholar 

  37. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.

    Article  CAS  PubMed  Google Scholar 

  38. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010;184(6):3260–8.

    Article  CAS  PubMed  Google Scholar 

  39. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80.

    Article  CAS  PubMed  Google Scholar 

  40. de Paula FJ, Rosen CJ. Vitamin D safety and requirements. Arch Biochem Biophys. 2012;523(1):64–72.

    Article  PubMed  CAS  Google Scholar 

  41. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011;126(2):295–310.

    Article  CAS  PubMed  Google Scholar 

  42. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–12.

    Article  CAS  PubMed  Google Scholar 

  43. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100(2):134–9.

    Article  CAS  PubMed  Google Scholar 

  45. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  PubMed  Google Scholar 

  46. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 2015; 107(3).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 1990;19(4):820–4.

    Article  CAS  PubMed  Google Scholar 

  49. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.

    Article  CAS  PubMed  Google Scholar 

  50. Green J, Clezardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010;37(Suppl 1):S3–11.

    Article  CAS  PubMed  Google Scholar 

  51. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women's health initiative. Cancer Res. 2003;63(18):6096–101.

    CAS  PubMed  Google Scholar 

  52. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat. 2012;131(3):915–24.

    Article  CAS  PubMed  Google Scholar 

  53. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12(6):214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.

    Article  CAS  PubMed  Google Scholar 

  55. Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26(4):589–600.

    Article  PubMed  Google Scholar 

  56. Jaroudi S, Peiris A. Vitamin D supplementation and cancer risk. JAMA. 2017;318(3):299.

    Article  PubMed  Google Scholar 

  57. Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, et al. The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prev Res (Phila). 2016;9(5):379–84.

    Article  CAS  Google Scholar 

  58. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971–1975 to 1992. National health and nutrition examination survey. Cancer Epidemiol Biomark Prev. 1999;8(5):399–406.

    CAS  Google Scholar 

  60. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121(4):302–9.

    Article  CAS  PubMed  Google Scholar 

  61. Kemmis CM, Salvador SM, Smith KM, Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr. 2006;136(4):887–92.

    Article  CAS  PubMed  Google Scholar 

  62. Kim S, Shore DL, Wilson LE, Sanniez EI, Kim JH, Taylor JA, et al. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 2015;15:960.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Krishnan AV, Swami S, Feldman D. Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention. J Steroid Biochem Mol Biol. 2013;136:289–95.

    Article  CAS  PubMed  Google Scholar 

  64. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev. 2008;17(5):1028–33.

    Article  CAS  Google Scholar 

  65. Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer. 2001;93(5):681–6.

    Article  CAS  PubMed  Google Scholar 

  66. Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017;317(12):1234–43.

    Article  CAS  PubMed  Google Scholar 

  67. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–91.

    Article  CAS  PubMed  Google Scholar 

  68. Liu C, Wu D, Zheng X, Li P, Li L. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther. 2015;17(2):142–8.

    Article  CAS  PubMed  Google Scholar 

  69. Liu Y, Zhao S, Chen W, Hu F, Zhu L, Zhang Q, et al. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature. Clin Breast Cancer. 2012;12(4):276–81.

    Article  PubMed  CAS  Google Scholar 

  70. Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8(25):40389–401.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012;131(2):581–7.

    Article  CAS  PubMed  Google Scholar 

  72. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008;17(2):115–24.

    Article  PubMed  Google Scholar 

  74. Marchionatti AM, Picotto G, Narvaez CJ, Welsh J, Tolosa de Talamoni NG. Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol. 2009;113(3–5):227–32.

    Article  CAS  PubMed  Google Scholar 

  75. Martinez JA, Chalasani P, Thomson CA, Roe D, Altbach M, Galons JP, et al. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. BMC Cancer. 2016;16:500.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Millen AE, Pettinger M, Freudenheim JL, Langer RD, Rosenberg CA, Mossavar-Rahmani Y, et al. Incident invasive breast cancer, geographic location of residence, and reported average time spent outside. Cancer Epidemiol Biomark Prev. 2009;18(2):495–507.

    Article  Google Scholar 

  77. Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol. 2013;28(5):554–60.

    Article  PubMed  Google Scholar 

  78. Monsees GM, Malone KE, Tang MT, Newcomb PA, Li CI. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2011;103(23):1752–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause. 2003;10(4):332–6.

    Article  PubMed  Google Scholar 

  80. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010;102(5):799–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821–30.

    Article  CAS  PubMed  Google Scholar 

  82. Nolan E, Donepudi M, VanWeelden K, Flanagan L, Welsh J. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem. 1998;188(1–2):13–20.

    Article  CAS  PubMed  Google Scholar 

  83. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (national surgical adjuvant breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359(13):1357–66.

    Article  CAS  PubMed  Google Scholar 

  85. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. Cancer. 2008;112(1):27–33.

    Article  PubMed  Google Scholar 

  86. Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol. 2006;24(13):2128–9 author reply 2129.

    Article  PubMed  Google Scholar 

  87. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109(3):533–43.

    Article  CAS  PubMed  Google Scholar 

  89. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28(22):3577–81.

    Article  CAS  PubMed  Google Scholar 

  90. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.

    Article  CAS  PubMed  Google Scholar 

  91. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.

    Article  CAS  PubMed  Google Scholar 

  92. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58(1):31–8.

    Article  CAS  PubMed  Google Scholar 

  93. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes. 2003;111(1):47–8.

    Article  CAS  PubMed  Google Scholar 

  94. Sharma ST, Wickham EP 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract. 2007;13(4):373–9.

    Article  PubMed  Google Scholar 

  95. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  96. Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–90.

    Article  CAS  PubMed  Google Scholar 

  97. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res. 1999;19(4B):2997–3006.

    CAS  PubMed  Google Scholar 

  98. Sprague JR, Wood ME. Statins and breast cancer prevention: time for randomized controlled trials. J Clin Oncol. 2006;24(13):2129–30 author reply 2130-2121.

    Article  PubMed  Google Scholar 

  99. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev. 2008;17(3):259–68.

    Article  PubMed  Google Scholar 

  100. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259–67.

    Article  CAS  PubMed  Google Scholar 

  101. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135(1):261–9.

    Article  CAS  PubMed  Google Scholar 

  102. Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int. 2011;88(4):255–62.

    Article  CAS  PubMed  Google Scholar 

  103. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, et al. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013;142(2):389–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134(2):875–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S–4S.

    Article  CAS  PubMed  Google Scholar 

  106. Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. Association of vitamin D3 level with breast cancer risk and prognosis in African-American and Hispanic women. Cancers (Basel). 2017;9(10).

    Article  PubMed Central  CAS  Google Scholar 

  107. Yang T, Yang Y, Liu S. Association between metformin therapy and breast cancer incidence and mortality: evidence from a meta-analysis. J Breast Cancer. 2015;18(3):264–70.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46(12):2196–205.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology Division, University of Vermont School of Medicine, Given E217, 89 Beaumont Ave, Burlington, VT, 05405, USA

    Naomi Hodde & Marie E. Wood

Authors
  1. Naomi Hodde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie E. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie E. Wood.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Risk and Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodde, N., Wood, M.E. Non-hormonal Chemoprevention. Curr Breast Cancer Rep 10, 313–318 (2018). https://doi.org/10.1007/s12609-018-0294-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-018-0294-7

Keywords

Search

Navigation